CoChat
Sign Up
Cited by 146Treatment of Major DepressionMental Health Treatment and AccessHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

The Economic Burden of Treatment-Resistant Depression

Olchanski, Natalia, McInnis Myers, Michelle, Halseth, Marilyn, Cyr, Philip L., Bockstedt, Lindsay, Goss, Thomas F., Howland, Robert H.·2013·Clinical Therapeutics
DOI 10.1016/j.clinthera.2012.09.001
Open this paper in CoChat — free account

Abstract

Background Major depressive disorder (MDD) is a leading cause of disability, morbidity, and mortality worldwide. The lifetime prevalence in the United States is estimated at 17%. Treatment-resistant depression (TRD) is generally defined as failure to achieve remissions despite adequate treatment. About 30% of patients do not achieve remission after 4 different antidepressant treatment trials. A few studies have examined the economic burden of TRD, but none has investigated the cost associated with more chronic and extensive forms of TRD characterized by nonresponse to ≥4 treatment trials.Objective The objective of this study was to compare the health care utilization (HCU) and direct medical expenditures of TRD patients with those of chronic MDD patients.Methods Patients with chronic MDD (defined as ≥2 years of continuous treatment) and patients with TRD (defined as undergoing at least 4 different qualifying antidepressant therapy trials) were identified in the PharMetrics Patient-centric Database. The association between TRD and medical expenditures was measured by using multivariate regression analysis.Results The classification of TRD had a clinically meaningful and statistically significant association with increased medical expenditures. Holding all else equal, the classification of TRD was associated with a 29.3% higher costs (P < 0.001) in medical expenditures compared with patients not meeting the study definition of TRD.Conclusions These results demonstrate that TRD is associated with significantly higher per-patient medical costs due to higher HCU. The findings suggest that the development of treatment alternatives for TRD is warranted. Limitations related to the use of secondary administrative data are noted.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2012.09.001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Rush, 2005, Vagus nerve stimulation for treatment-resistant depression: a randomized controlled acute phase trial, Biol Psychiatry, 58, 347, 10.1016/j.biopsych.2005.05.025 · DOI · Paper page

Cited by

Sorted by citations

See all 146

Related

See all

Metadata

Authors
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H.
Affiliations
  • Medtronic (United States) (US)
  • University of Pittsburgh (US)
ORCID
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2013-04
Volume
35
Issue
4
Pages
512-522
ISSN
0149-2918 (ISSN-L)
DOI
10.1016/j.clinthera.2012.09.001
OpenAlex
W2064476618
Cited by
146
References
27
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 14 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 18 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 11 · 2013: 3
FWCI
7.10
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Medtronic
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
treatment-resistant depression, major depressive disorder, chronic depression, economic burden, health care utilization, health care costs, direct medical costs
MeSH terms
Depression, Female, Humans, Male, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review